Loading…
Owns and markets a portfolio of over-the-counter consumer health and personal-care brands sold at retail.
Owns and markets a portfolio of over-the-counter consumer health and personal-care brands sold at retail.
Buys established over-the-counter brands that larger companies treat as too small, outsources almost all manufacturing to contract makers, and spends on advertising to hold shelf space. Walmart is its largest customer. Sales are mostly in North America, with smaller bases in Australia and elsewhere.
Moat: narrow (brand, distribution). Long-established OTC brand names hold trusted shelf space that is hard for new entrants to win.
Headquarters: Tarrytown, New York, US · Founded: 1996 · Employees: 890
Size Prestige Consumer Healthcare (PBH) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.04B, the 1778th largest of 3,117 United States companies the cockpit tracks. Shares closed at $42.98 on 6 Nov 2026.
Performance Over six months the shares fell 18.2%, against -6.3% for the median peer and -1.1% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue fell 1.4% over the last twelve months (peer median +5.0%); the operating margin is 26.3% (peer median 11.0%).
Valuation It trades at 9.3× forward earnings against a peer median of 22.9× (cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.0 points below its cost of capital (5.9% WACC).
Short interest Short interest is 8.4% of the free float (15 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.10B | $1.09B | $1.14B | $1.13B | $1.13B |
| Revenue growth | — | -4% | +1% | 0% | — |
| Gross profit | $570M | $575M | $613M | $602M | $600M |
| EBITDA | $323M | $341M | $379M | $373M | $387M |
| Net income | $172M | $190M | $215M | $209M | -$82.3M |
| Free cash flow | $235M | $246M | $243M | $239M | $222M |
| Capital expenditure | $14.0M | $11.2M | $8.22M | $9.55M | $7.78M |
| Total debt | $2.07B | $1.05B | $1.04B | $1.14B | $1.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Prestige Consumer Healthcare PBH | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% |
| Kenvue KVUE | n/a | +12% | n/a | n/a | n/a | n/a |
| Haleon HLN.L | $40.1B | +1% | +1% | 23% | 16.3× | 4.6% |
| Church & Dwight CHD | $25.8B | +17% | +2% | 18% | 27.4× | 6.9% |
| Reckitt Benckiser RKT.L | $47.6B | +22% | -2% | 28% | 16.4× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PBH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.2% | -0.8% | 4th lowest of 21 |
| 6-month return | -18.2% | -6.3% | 8th lowest of 21 |
| Distance from 52-week high | -39.5% | -28.9% | 8th lowest of 21 |
| Revenue growth (TTM) | -1.4% | +5.0% | 7th lowest of 21 |
| Operating margin | 26.3% | 11.0% | 3rd highest of 21 |
| Forward P/E | 9.3× | 22.9× | cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -0.2% | 7.6% | 5th least demanding of 17 |
| Growth delivered (Del g) | +2.9% | +7.9% | 5th lowest of 17 |
| Hurdle (Req g minus delivered) | -3.1 pp | -0.2 pp | 8th least demanding of 17 |
| ROIC minus cost of capital | -0.0 pp | -1.7 pp | 10th highest of 21 |
| EV / EBITDA | 12.4× | 11.4× | 4th cheapest of 7 |
| Net debt / EBITDA | 6.1× | 1.5× | most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% | +15.7% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | n/a | 37.9% | +0.9% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 22.8× | 6.1% | +6.4% |